New eczema pill shows promise in Mid-Stage trial

NCT ID NCT07216027

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times

Summary

This study tests whether a new daily pill, PF-08049820, can safely reduce itching and rash in adults with moderate to severe eczema. About 200 participants will take either the study drug or a placebo for 12 weeks, with regular checkups to track skin improvement. The goal is to see if the drug eases symptoms better than a placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Clinical Science Institute

    Santa Monica, California, 90404, United States

  • Dermatology and Ophthalmology Kume Clinic

    Sakai, Osaka, 593-8324, Japan

  • Fukuwa Clinic

    Chuo-ku, Tokyo, 104-0031, Japan

  • Goodlettsville Dermatology Research

    Goodlettsville, Tennessee, 37072, United States

  • Gsi Clinical Research

    Margate, Florida, 33063, United States

  • Hattori Dermatology Clinic

    Takasaki, Gunma, 370-0071, Japan

  • Kosugi Dermatology Clinic

    Kawasaki-shi, Kanagawa, 211-0063, Japan

  • Nihonbashi Sakura Clinic

    Chuo-ku, Tokyo, 103-0025, Japan

  • Queen's Square Medical Facilities

    Yokohama, Kanagawa, 220-6208, Japan

  • Skin Research of South Florida

    Miami, Florida, 33173, United States

Conditions

Explore the condition pages connected to this study.